The effect of orally administered epigallocatechin-3-gallate on ligature-induced periodontitis in rats

A. R. Cho, J. H. Kim, D. E. Lee, J. S. Lee, Ui-Won Jung, E. J. Bak, Y. J. Yoo, W. G. Chung, Seongho Choi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background and Objective: Epigallocatechin-3-gallate (EGCG) is known for its beneficial properties, including anti-inflammatory and anti-oxidative activities. Recently, reports have suggested that EGCG plays a pivotal role in regulating cytokine expression and osteoclastic activity. In the present study, we investigated whether orally administered EGCG has a therapeutic effect on ligature-induced periodontitis. Materials and Methods: Forty-eight Sprague-Dawley rats were treated with EGCG or phosphate-buffered saline. Periodontitis was induced by tying a ligature for 7 d. After removing ligation, EGCG (200 mg/kg) or phosphate-buffered saline was administered via oral gavage on a daily basis. Rats were killed after 1, 2 and 4 wk of administration. Histologic and histomorphometric analyses, tartrate resistant acid phosphatase staining and immunohistochemistry were carried out. Results: In the control group, bone loss did not recover even after the causative factor of periodontitis was eliminated. On the other hand, distance from cemento-enamel junction to alveolar bone crest, long junctional epithelium and collagen destruction were reduced in the EGCG group. Decreased interleukin (IL)-6 expression was shown from the early stage of EGCG administration, followed by reduced tumor necrosis factor (TNF) expression at week 4 EGCG group. The CT area showed a higher decrease of IL-6 expression between the control and EGCG group than alveolar bone area. Downregulation of TNF and IL-6 expression led to a decrease in osteoclast number and activity, which resulted in reduced bone loss. Conclusions: Systemic administration of EGCG could have a therapeutic effect on damaged periodontal tissue. Inhibited cytokine expression, including TNF and IL-6 is responsible for the reduction in osteoclast formation, osteoclastic activity and collagen destruction.

Original languageEnglish
Pages (from-to)781-789
Number of pages9
JournalJournal of Periodontal Research
Volume48
Issue number6
DOIs
Publication statusPublished - 2013 Dec 1

Fingerprint

Periodontitis
Ligation
Interleukin-6
Bone and Bones
Tumor Necrosis Factor-alpha
Therapeutic Uses
Osteoclasts
Collagen
Phosphates
Epithelial Attachment
epigallocatechin gallate
Cytokines
Dental Enamel
Sprague Dawley Rats
Anti-Inflammatory Agents
Down-Regulation
Immunohistochemistry
Staining and Labeling
Control Groups

All Science Journal Classification (ASJC) codes

  • Periodontics

Cite this

Cho, A. R. ; Kim, J. H. ; Lee, D. E. ; Lee, J. S. ; Jung, Ui-Won ; Bak, E. J. ; Yoo, Y. J. ; Chung, W. G. ; Choi, Seongho. / The effect of orally administered epigallocatechin-3-gallate on ligature-induced periodontitis in rats. In: Journal of Periodontal Research. 2013 ; Vol. 48, No. 6. pp. 781-789.
@article{f0124616be684a488232b7c7aa838b19,
title = "The effect of orally administered epigallocatechin-3-gallate on ligature-induced periodontitis in rats",
abstract = "Background and Objective: Epigallocatechin-3-gallate (EGCG) is known for its beneficial properties, including anti-inflammatory and anti-oxidative activities. Recently, reports have suggested that EGCG plays a pivotal role in regulating cytokine expression and osteoclastic activity. In the present study, we investigated whether orally administered EGCG has a therapeutic effect on ligature-induced periodontitis. Materials and Methods: Forty-eight Sprague-Dawley rats were treated with EGCG or phosphate-buffered saline. Periodontitis was induced by tying a ligature for 7 d. After removing ligation, EGCG (200 mg/kg) or phosphate-buffered saline was administered via oral gavage on a daily basis. Rats were killed after 1, 2 and 4 wk of administration. Histologic and histomorphometric analyses, tartrate resistant acid phosphatase staining and immunohistochemistry were carried out. Results: In the control group, bone loss did not recover even after the causative factor of periodontitis was eliminated. On the other hand, distance from cemento-enamel junction to alveolar bone crest, long junctional epithelium and collagen destruction were reduced in the EGCG group. Decreased interleukin (IL)-6 expression was shown from the early stage of EGCG administration, followed by reduced tumor necrosis factor (TNF) expression at week 4 EGCG group. The CT area showed a higher decrease of IL-6 expression between the control and EGCG group than alveolar bone area. Downregulation of TNF and IL-6 expression led to a decrease in osteoclast number and activity, which resulted in reduced bone loss. Conclusions: Systemic administration of EGCG could have a therapeutic effect on damaged periodontal tissue. Inhibited cytokine expression, including TNF and IL-6 is responsible for the reduction in osteoclast formation, osteoclastic activity and collagen destruction.",
author = "Cho, {A. R.} and Kim, {J. H.} and Lee, {D. E.} and Lee, {J. S.} and Ui-Won Jung and Bak, {E. J.} and Yoo, {Y. J.} and Chung, {W. G.} and Seongho Choi",
year = "2013",
month = "12",
day = "1",
doi = "10.1111/jre.12071",
language = "English",
volume = "48",
pages = "781--789",
journal = "Journal of Periodontal Research",
issn = "0022-3484",
publisher = "Blackwell Munksgaard",
number = "6",

}

The effect of orally administered epigallocatechin-3-gallate on ligature-induced periodontitis in rats. / Cho, A. R.; Kim, J. H.; Lee, D. E.; Lee, J. S.; Jung, Ui-Won; Bak, E. J.; Yoo, Y. J.; Chung, W. G.; Choi, Seongho.

In: Journal of Periodontal Research, Vol. 48, No. 6, 01.12.2013, p. 781-789.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of orally administered epigallocatechin-3-gallate on ligature-induced periodontitis in rats

AU - Cho, A. R.

AU - Kim, J. H.

AU - Lee, D. E.

AU - Lee, J. S.

AU - Jung, Ui-Won

AU - Bak, E. J.

AU - Yoo, Y. J.

AU - Chung, W. G.

AU - Choi, Seongho

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Background and Objective: Epigallocatechin-3-gallate (EGCG) is known for its beneficial properties, including anti-inflammatory and anti-oxidative activities. Recently, reports have suggested that EGCG plays a pivotal role in regulating cytokine expression and osteoclastic activity. In the present study, we investigated whether orally administered EGCG has a therapeutic effect on ligature-induced periodontitis. Materials and Methods: Forty-eight Sprague-Dawley rats were treated with EGCG or phosphate-buffered saline. Periodontitis was induced by tying a ligature for 7 d. After removing ligation, EGCG (200 mg/kg) or phosphate-buffered saline was administered via oral gavage on a daily basis. Rats were killed after 1, 2 and 4 wk of administration. Histologic and histomorphometric analyses, tartrate resistant acid phosphatase staining and immunohistochemistry were carried out. Results: In the control group, bone loss did not recover even after the causative factor of periodontitis was eliminated. On the other hand, distance from cemento-enamel junction to alveolar bone crest, long junctional epithelium and collagen destruction were reduced in the EGCG group. Decreased interleukin (IL)-6 expression was shown from the early stage of EGCG administration, followed by reduced tumor necrosis factor (TNF) expression at week 4 EGCG group. The CT area showed a higher decrease of IL-6 expression between the control and EGCG group than alveolar bone area. Downregulation of TNF and IL-6 expression led to a decrease in osteoclast number and activity, which resulted in reduced bone loss. Conclusions: Systemic administration of EGCG could have a therapeutic effect on damaged periodontal tissue. Inhibited cytokine expression, including TNF and IL-6 is responsible for the reduction in osteoclast formation, osteoclastic activity and collagen destruction.

AB - Background and Objective: Epigallocatechin-3-gallate (EGCG) is known for its beneficial properties, including anti-inflammatory and anti-oxidative activities. Recently, reports have suggested that EGCG plays a pivotal role in regulating cytokine expression and osteoclastic activity. In the present study, we investigated whether orally administered EGCG has a therapeutic effect on ligature-induced periodontitis. Materials and Methods: Forty-eight Sprague-Dawley rats were treated with EGCG or phosphate-buffered saline. Periodontitis was induced by tying a ligature for 7 d. After removing ligation, EGCG (200 mg/kg) or phosphate-buffered saline was administered via oral gavage on a daily basis. Rats were killed after 1, 2 and 4 wk of administration. Histologic and histomorphometric analyses, tartrate resistant acid phosphatase staining and immunohistochemistry were carried out. Results: In the control group, bone loss did not recover even after the causative factor of periodontitis was eliminated. On the other hand, distance from cemento-enamel junction to alveolar bone crest, long junctional epithelium and collagen destruction were reduced in the EGCG group. Decreased interleukin (IL)-6 expression was shown from the early stage of EGCG administration, followed by reduced tumor necrosis factor (TNF) expression at week 4 EGCG group. The CT area showed a higher decrease of IL-6 expression between the control and EGCG group than alveolar bone area. Downregulation of TNF and IL-6 expression led to a decrease in osteoclast number and activity, which resulted in reduced bone loss. Conclusions: Systemic administration of EGCG could have a therapeutic effect on damaged periodontal tissue. Inhibited cytokine expression, including TNF and IL-6 is responsible for the reduction in osteoclast formation, osteoclastic activity and collagen destruction.

UR - http://www.scopus.com/inward/record.url?scp=84887188664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887188664&partnerID=8YFLogxK

U2 - 10.1111/jre.12071

DO - 10.1111/jre.12071

M3 - Article

C2 - 23581513

AN - SCOPUS:84887188664

VL - 48

SP - 781

EP - 789

JO - Journal of Periodontal Research

JF - Journal of Periodontal Research

SN - 0022-3484

IS - 6

ER -